A novel strategy, targeting glycolytic system for radiation resistant head and neck cancer

Research Project

Project/Area Number	15H06379
Research Category	Grant-in-Aid for Research Activity Start-up
Allocation Type	Single-year Grants
Research Field	Otorhinolaryngology
Research Institution	Osaka University
Principal Investigator	Junji Miyabe 大阪大学, 医学部附属病院, 医員 (60756831)
Project Period (FY)	2015-08-28 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000) Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	頭頸部癌 / 放射線抵抗性 / 解糖系 / MCT4 / 放射線抵抗性頭頸部癌 / トランスポーター
Outline of Final Research Achievements	Monocarboxylate transporter 4 (MCT4) is a transporter of lactate. I confirmed the expression of MCT4 in head and neck cancer cell lines (Fadu, Detroit562, BICR6). I used small-interfering RNA to silence its expression. I demonstrated that knock-down of MCT4 decreased cell proliferation. Hypoxic condition induced the cell proliferation in Fadu cell line. Knock-down of MCT4 suppressed the cell proliferation in hypoxic condition. It is reported that hypoxia induces radioresistance. These results suggest that knock down of MCT4 may suppress the cell proliferation of hypoxia-induced radioresistant cancer.

Report

(3 results)